Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.
about
How does the efficacy and safety of Oralair(®) compare to other products on the market?Recommendations for appropriate sublingual immunotherapy clinical trialsMite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?Sublingual immunotherapy: World Allergy Organization position paper 2013 update.Sublingual immunotherapy in children with allergic rhinitis: quality of systematic reviews.Randomized double-blind placebo-controlled trial of sublingual immunotherapy in children with house dust mite allergy in primary care: study design and recruitment.Strategies of mucosal immunotherapy for allergic diseasesBasophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapyIntradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms.Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters in clinical studies.A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitisSystematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.Treatment of grass pollen allergy: focus on a standardized grass allergen extract - Grazax®.The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.Three-Year Follow-up Results of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitized to House Dust MitesSafety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis.Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined scoreGuideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical AssoAllergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella reviewAllergic Rhinitis and Its Impact on Asthma in Asia Pacific and the ARIA Update 2008Prospective validation of the "rhino conjunctivitis allergy-control-SCORE©" (RC-ACS©).Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes.The paucity of ethical analysis in allergology.Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper.Regulatory aspects of allergen-specific immunotherapy: europe sets the scene for a global approach.The efficacy assessment of a self-administered immunotherapy protocolEvidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany.A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma.Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitisAllergy vaccines: dreams and reality.Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE).Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis.Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study.A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia).House dust mite sublingual tablet is effective and safe in patients with allergic rhinitisEmerging sublingual immunotherapy drugs.Clinical practice: Allergen-specific immunotherapy in children: facts and FAQs.Specific immunotherapy in asthma: efficacy and safety.Regulatory environment for allergen-specific immunotherapy.
P2860
Q26745596-8458B1DC-F39A-46F6-82CF-9DEAA6E4E670Q27011713-86C45B11-D97D-4DCA-8E1F-27A5F5C96A22Q28082353-63AD043C-3E81-493B-877C-C4A080F563AAQ30440195-776B8A57-6142-4291-A3F2-DD0881B3C1ACQ31030974-43CA8A04-CC77-4E9E-93F2-DDCE3997F252Q33378244-C90BE600-BE1F-498C-90ED-2D9F4DE47956Q33577679-F2505E5F-5D4E-4020-9D05-1C8EF6B48BFAQ33702206-DA0C1A1E-AAEB-4901-A811-6233FFF12EBCQ33758296-B18E9004-255C-4439-89C0-1B7415AF9FFCQ33781950-165C994F-C9E9-4BF5-A526-40AE45F1E972Q33914193-D1A4F684-2F4B-4D8C-93E5-BC9A7DC7DE85Q34221237-D3499207-2D0C-48AB-B5DC-552E54E24791Q34548671-18537FE2-8E97-440E-9141-843745201A88Q34606056-5A988856-18C6-47F6-9B92-187C7F477A45Q35005943-5F4EB5DF-ACE8-4E1D-B0C0-9FB7E04CCD4CQ35123899-64C0ABB8-8079-4B45-BFA6-B4D2FA293A40Q35211932-6626EF6E-89CF-4AEB-8471-7FD42FC77A71Q35761230-5E099C59-7588-4A5D-8FF9-10DFD547CD0CQ35777126-F16A3AE2-C082-4F82-B235-2C547791E990Q36369716-55A3C1FF-4353-4D5E-9561-6224AC70B4ADQ36371027-D7376C34-DB98-40DA-B46D-58F3DA0D0706Q36376780-69366FA0-D859-4095-A3B8-3531AE0228E2Q36379784-49BD0B36-2680-4EE8-BCAB-A31C4A1EF029Q36614125-2D5AA008-81A3-41C9-9327-D2CF9298A5A6Q36834756-3C10D456-0E5E-41C7-9E8B-681F629FE820Q36834860-90B58378-98D6-4868-BD8E-567638BAD53AQ36881918-CBF8FC79-91D9-4525-A2F1-B74B3BF5FBBCQ36885641-8DF0688A-F4B2-4645-8404-E4AE066B3ED6Q36945591-9A648DF3-E513-4615-98C2-9C1AA270D870Q37013813-8FB859EF-76B4-4B77-A08E-7C680CF59F66Q37123463-C2FFCAD7-2383-4A71-9302-C88CDB5A1B54Q37153212-1D171142-25C9-4C00-829B-9377DC833EBDQ37231881-9F5BAAAF-9713-4129-991F-386438AA9A61Q37591378-53605B43-B8CD-41D8-B43A-F3E4A31DE634Q37652965-B4E49B7F-69D8-407A-AED7-10CE26BDDD83Q37663911-0A0D801B-F760-4DE7-A7D5-6177C7FCF096Q37801372-7BC30DBE-1FC4-41BA-B341-7D275BC52132Q37820336-CB31821C-CD89-45E6-BA5E-55A33238782FQ37831393-717DDE8F-BD48-4662-A249-883C03B5E1D6Q37834696-9CC7D7BD-6254-478E-8260-1B2AAD290F34
P2860
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Recommendations for standardiz ...... Organization (WAO) taskforce.
@ast
Recommendations for standardiz ...... Organization (WAO) taskforce.
@en
type
label
Recommendations for standardiz ...... Organization (WAO) taskforce.
@ast
Recommendations for standardiz ...... Organization (WAO) taskforce.
@en
prefLabel
Recommendations for standardiz ...... Organization (WAO) taskforce.
@ast
Recommendations for standardiz ...... Organization (WAO) taskforce.
@en
P2093
P1433
P1476
Recommendations for standardiz ...... y Organization (WAO) taskforce
@en
P2093
Baena-Cagnani CE
Bousquet J
Bousquet PJ
Malling HJ
Passalacqua G
Valovirta E
P2860
P304
P356
10.1111/J.1398-9995.2006.01312.X
P577
2007-03-01T00:00:00Z